On this episode of Managed Care Cast, we speak with the new chief financial officer of Strive Health, a value-based kidney care company that works with payers and providers to create an integrated care delivery system for chronic kidney disease and end-stage renal disease (ESRD). We discuss the changes coming to nephrology practices, as well as new ways of looking at the whole patient to halt the slide to irreversible ESRD.
In 2021, CMS is launching new payment models to address the high cost of care for Medicare beneficiaries with kidney disease and to improve patient outcomes. Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are among the most expensive conditions in Medicare; about 37 million Americans have CKD and 725,000 have ESRD. The situation is expected to get worse as the population ages, rates of diabetes and obesity soar, and demand for dialysis increases.
On this episode of Managed Care Cast, we speak with Brandi Riddle, who recently joined Strive Health as its chief financial officer. Strive Health is a value-based kidney care company that works with payers and providers to create an integrated care delivery system for CKD and ESRD. We discuss the changes coming to nephrology practices, as well as new ways of looking at the whole patient to try and halt the slide to irreversible ESRD.
Listen above or through one of these podcast services:
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More